The New Provisional WHO Entity ‘RUNX1 Mutated AML’ Shows Specific Genetics but No Prognostic Influence of Dysplasia

Leukemia - United Kingdom
doi 10.1038/leu.2016.150
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Prognostic Models Turn the Heat(IT)up on FLT3ITD-mutated AML

Clinical Cancer Research
Cancer ResearchOncology
2018English

NPM1 Mutant Variant Allele Frequency Correlates With Leukemia Burden but Does Not Provide Prognostic Information in NPM1-mutated AML

American Journal of Hematology
Hematology
2019English

Molecular Genetics of AML

Best Practice and Research in Clinical Haematology
OncologyClinical Biochemistry
2012English

Recurrent Somatic JAK-STAT Pathway Variants Within a RUNX1-mutated Pedigree

European Journal of Human Genetics
Genetics
2017English

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discovery
Oncology
2013English

Who Owns Plant Genetics?

Nature Genetics
Genetics
2000English

A New Time-Dependent Approach for Assessment of the Impact of Invasive Aspergillosis Shows Effect on Short- But Not on Long-Term Survival of Patients With AML or High-Risk MDS

Bone Marrow Transplantation
TransplantationHematology
2017English

Situs Inversus Totalis, Renal and Pancreatic Dysplasia, and Cysts as an Autosomal Recessive New Entity?

Genetics in Medicine
MedicineGenetics
2007English

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-Aml Cells

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy